Pharming Group Q3 2026 TU Earnings Date & Estimates

Pharming Group (NASDAQ:PHAR) N.V. is a biopharmaceutical company headquartered in Leiden, the Netherlands. The company develops and commercializes medicines for rare diseases and operates internationally, serving patients and healthcare providers in North America, Europe and other selected markets.

Pharming’s principal product is Ruconest, a recombinant C1 esterase inhibitor used to treat acute attacks of hereditary angioedema, a rare genetic disorder that can cause potentially serious swelling. The company also markets Joenja (leniolisib), an oral treatment for activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency. Joenja received approval in the United States and has subsequently been subject to regulatory activity in other jurisdictions.

Founded in 1988, Pharming has focused on the development of human therapeutic proteins produced through recombinant technology. Its activities include research and development, regulatory support, manufacturing coordination and the commercialization of treatments for underserved rare-disease populations. Pharming Group’s shares are listed on Euronext Amsterdam, and its American Depositary Shares trade on Nasdaq under the symbol PHAR.